866-997-4948(US-Canada Toll Free)

Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Sep 2015

Category :

Cancer

No. of Pages : 159 Pages

Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2015, provides an overview of the Human papillomavirus (HPV) Associated Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Human papillomavirus (HPV) Associated Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Human papillomavirus (HPV) Associated Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Human papillomavirus (HPV) Associated Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Human papillomavirus (HPV) Associated Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Overview 9
Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis 10
Human papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 11
Human papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 13
Human papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Human papillomavirus (HPV) Associated Cancer - Products under Development by Companies 17
Human papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 20
Human papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 21
3SBio Inc. 21
Admedus Ltd 22
Advaxis, Inc. 23
Antigen Express, Inc. 24
Bionor Pharma ASA 25
Cancer Research Technology Limited 26
Cancer Therapeutics CRC Pty Ltd 27
Chong Kun Dang Pharmaceutical Corp. 28
Etubics Corporation 29
EyeGene, Inc. 30
Formune S.L. 31
Genexine, Inc. 32
iBio, Inc. 33
Immunovaccine, Inc. 34
Inovio Pharmaceuticals, Inc. 35
Karyopharm Therapeutics, Inc. 36
Kite Pharma, Inc. 37
MedImmune, LLC 38
Merck & Co., Inc. 39
Novartis AG 40
Onconova Therapeutics, Inc. 41
Oryx GmbH & Co. KG 42
Prima BioMed Ltd. 43
Profectus BioSciences, Inc. 44
Redbiotec AG 45
Shantha Biotechnics Limited 46
Sirnaomics, Inc. 47
Theravectys SA 48
Transgene SA 49
Vaccibody AS 50
Virometix AG 51
ViroStatics, srl 52
Human papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Target 55
Assessment by Mechanism of Action 57
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
AEH-10p - Drug Profile 63
alpelisib - Drug Profile 64
Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 66
Antibodies to Target E7 for HPV Associated Cancer - Drug Profile 67
Cell Therapy for HPV Associated Cancers - Drug Profile 68
Cell Therapy for HPV-Associated Cancer and Cervical Cancer - Drug Profile 69
Cell Therapy for HPV-Associated Cancer and Head and Neck Cancer - Drug Profile 71
Cell Therapy to Target HPV-16 E6 Protein for Cancer - Drug Profile 73
CKD-12201 - Drug Profile 74
CTX-0197195 - Drug Profile 75
CTX-0272859 - Drug Profile 76
CTX-0291736 - Drug Profile 77
DPV-001 - Drug Profile 78
DPX-E7 - Drug Profile 80
durvalumab + tremelimumab - Drug Profile 81
EDA-HPVE7 - Drug Profile 83
EG-HPV - Drug Profile 84
GX-188E - Drug Profile 85
human papillomavirus (7-valent) vaccine - Drug Profile 86
human papillomavirus (9-valent) vaccine - Drug Profile 87
human papillomavirus [Serotype 16] vaccine - Drug Profile 88
human papillomavirus vaccine - Drug Profile 89
human papillomavirus vaccine - Drug Profile 90
human papillomavirus vaccine - Drug Profile 91
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 92
INO-3106 - Drug Profile 93
INO-3112 - Drug Profile 94
Lm-LLO-ISG15 - Drug Profile 95
NP-001 - Drug Profile 97
NTCP-02 - Drug Profile 98
Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 99
RBT-201 - Drug Profile 100
rigosertib sodium - Drug Profile 101
sdCMV-002 - Drug Profile 106
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile 107
Small Molecules for HPV Associated Cancer - Drug Profile 108
SSS-08 - Drug Profile 109
STP-909 - Drug Profile 110
STP-911 - Drug Profile 111
TA-CIN - Drug Profile 112
TG-4001 - Drug Profile 114
TT-12 - Drug Profile 116
Vacc-HPV - Drug Profile 117
Vaccine for HIV and HPV Associated Cancer - Drug Profile 118
Vaccine for HPV Associated Cancer - Drug Profile 119
Vaccine for HPV Associated Cancer - Drug Profile 120
Vaccine for HPV Associated Cancers - Drug Profile 121
Vaccine for HPV Associated Head and Neck Squamous Cell Carcinoma - Drug Profile 122
Vaccine for HPV Associated Skin Cancer - Drug Profile 123
Vaccine HPV Associated Cancer - Drug Profile 124
Vaccines for HPV Associated Cervical Cancer - Drug Profile 125
VB-1016 - Drug Profile 126
verdinexor - Drug Profile 127
Vicoryx - Drug Profile 128
Human papillomavirus (HPV) Associated Cancer - Recent Pipeline Updates 129
Human papillomavirus (HPV) Associated Cancer - Dormant Projects 145
Human papillomavirus (HPV) Associated Cancer - Product Development Milestones 146
Featured News & Press Releases 146
Appendix 154
Methodology 154
Coverage 154
Secondary Research 154
Primary Research 154
Expert Panel Validation 154
Contact Us 154
Disclaimer 155

List of Tables
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H2 2015 13
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Development, H2 2015 20
Products under Development by Companies, H2 2015 21
Products under Development by Companies, H2 2015 (Contd..1) 22
Products under Development by Companies, H2 2015 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2015 24
Human papillomavirus (HPV) Associated Cancer - Pipeline by 3SBio Inc., H2 2015 25
Human papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H2 2015 26
Human papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis, Inc., H2 2015 27
Human papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H2 2015 28
Human papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H2 2015 29
Human papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Limited, H2 2015 30
Human papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2015 31
Human papillomavirus (HPV) Associated Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 32
Human papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H2 2015 33
Human papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H2 2015 34
Human papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H2 2015 35
Human papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H2 2015 36
Human papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H2 2015 37
Human papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine, Inc., H2 2015 38
Human papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 39
Human papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 40
Human papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma, Inc., H2 2015 41
Human papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H2 2015 42
Human papillomavirus (HPV) Associated Cancer - Pipeline by Merck & Co., Inc., H2 2015 43
Human papillomavirus (HPV) Associated Cancer - Pipeline by Novartis AG, H2 2015 44
Human papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H2 2015 45
Human papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2015 46
Human papillomavirus (HPV) Associated Cancer - Pipeline by Prima BioMed Ltd., H2 2015 47
Human papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences, Inc., H2 2015 48
Human papillomavirus (HPV) Associated Cancer - Pipeline by Redbiotec AG, H2 2015 49
Human papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Limited, H2 2015 50
Human papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H2 2015 51
Human papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H2 2015 52
Human papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H2 2015 53
Human papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H2 2015 54
Human papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H2 2015 55
Human papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics, srl, H2 2015 56
Assessment by Monotherapy Products, H2 2015 57
Assessment by Combination Products, H2 2015 58
Number of Products by Stage and Target, H2 2015 60
Number of Products by Stage and Mechanism of Action, H2 2015 62
Number of Products by Stage and Route of Administration, H2 2015 64
Number of Products by Stage and Molecule Type, H2 2015 66
Human papillomavirus (HPV) Associated Cancer Therapeutics - Recent Pipeline Updates, H2 2015 133
Human papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2015 149

List of Figures
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H2 2015 13
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Products, H2 2015 20
Assessment by Monotherapy Products, H2 2015 57
Number of Products by Top 10 Targets, H2 2015 59
Number of Products by Stage and Top 10 Targets, H2 2015 59
Number of Products by Top 10 Mechanism of Actions, H2 2015 61
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 61
Number of Products by Top 10 Routes of Administration, H2 2015 63
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 63
Number of Products by Top 10 Molecule Types, H2 2015 65
Number of Products by Stage and Top 10 Molecule Types, H2 2015 65

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *